BioXcel scores another win with reformulated Pfizer sedative, this time in an Alzheimer's symptom

Less than six months after reporting positive Phase III results for its lead program in treating agitation related to schizophrenia and bipolar disorder, small AI biotech BioXcel followed up Tuesday with top-line data in an early stage trial for agitation in dementia and Alzheimer’s disease.